Comparison · NCT01843374-522c949a
TREMELIMUMAB vs PLACEBO: Number of Participants With Positive Anti-drug Antibodies
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TREMELIMUMAB vs PLACEBO: Number of Participants With Positive Anti-drug Antibodies. Trial comparisons, record NCT01843374-522c949a. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01843374-522c949a
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0398 | 0.0243 | 0.0646 | wilson | |
| Risk in group 2 | 0 | 0 | 0.02 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0398 | 0.0144 | 0.0646 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on TREMELIMUMAB than on PLACEBO | 25.1 | 15.5 | 69.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TREMELIMUMAB | Tremelimumab 10mg/kg | 15 | 377 | OG001 |
| Group 2 | PLACEBO | Placebo. | 0 | 188 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Positive Anti-drug Antibodies
- Description
- The immunogenicity titer is reported for samples confirmed positive for the presence of anti tremelimumab antibodies.
- Time frame
- Week 5
- Population
- Safety population
Source ClinicalTrials.gov
Trial
- Title
- Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
- NCT number
- NCT01843374
- Phases
- PHASE2
- Conditions
- Unresectable Pleural or Peritoneal Malignant Mesothelioma
- Interventions
- Tremelimumab, Placebo
- Lead sponsor
- MedImmune LLC
- Results first posted
- 2017-08-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01843374?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01843374-522c949a